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Poster Session II 103determined by a PCR assay before UD transplant would be associ-
ated with a higher incidence of HC.Methods:We studied prospec-
tively 209 consecutive patients transplanted from 09/05 to 08/07.
Preparative regimens were ablative (n5 118) and reduced intensity
(n5 91); 38 patients (18%) received cyclophosphamide-containing
regimens. GVHD prophylaxis was tacrolimus and mini-methotrex-
ate. Stem cell source was bone marrow (n 5 78), peripheral blood
(n 5 108) and umbilical cord (n 5 23). BK virus quantitative PCR
was performed on urine samples collected at admission for trans-
plant and on days 15, 30, 45 and 60 after transplant. Results: Me-
dian age was 49 years (range, 19–71). Diagnoses were Leukemias
(n 5 161), Multiple Myeloma (n 5 6), Hodgkin’s disease (n 5 7),
Non-Hodgkin’s Lymphomas (n 5 32), and other(n 5 3). Median
follow-up is 246 days (range 7–848). BK PCR was positive in 96 pa-
tients(46%). Number of viral copies ranged from 200 to.200 mil-
lion copies. Twenty-eight patients (13.4%) developed HC, at
a median of 59 days (range 8–225) after HSCT. The 100-day cumu-
lative incidence (using death as a competing risk) of HC in the PCR
positive and negative groups was 13% versus 6% (HR 2.6; 95% CI,
1–6.9; P 5 0.05). The one-year cumulative incidence of HC in the
PCR positive and negative groups was 16% versus 10% (HR 2; 95%
CI, 0.9–4.6; P5 0.09). Incidence of HC (table) was not statistically
significantly increased among recipients of cyclophosphamide-con-
taining regimens or among patients with grade II-IV acute GVHD.
Conclusion: BK viruria pre-HSCT may increase the risk of devel-
oping HC.Incidence of HC
HC Yes (n) %non CTX regimen 20 11
CTX regimen 4 10
GVHD II-IV 8 12
non GVHD 9 10
Ablative regimen 18 15
non-Ablative regimen 6 6
Stem Cell Source
PBSC 13 12
BM 6 7
CB 5 21
BK PCR. 200 million copies 2 25
BK PCR\200 million copies 13 15HC: Hemorrhagic Cystitis; CTX: Cyclophosphamide; PBSC:
Peripheral Blood Stem Cell; BM Bone Marrow; CB: Cord
Blood.278
TREOSULFAN PLUS FLUDARABINE FOR ALLOGENEIC HEMATOPOIETIC
CELL TRANSPLANTATION (HCT) IN PATIENTS WITH ACUTE LEUKEMIA
AND MYELODYSPLASTIC SYNDROME
Nemecek, E.R.1, Ly, B.2, Kovacsovics, T.2, Maziarz, R.T.2,
Baumgart, J.3, Sanders, J.E.4, Deeg, H.J.4. 1Oregon Health & Science
University, Portland, OR; 2Oregon Health & Science University,
Portland, OR; 3Medac GmbH, Hamburg, Germany; 4Fred Hutchinson
Cancer Research Center, Seattle, WA.
Myeloablative regimens followed by allogeneic HCT are effec-
tive in eradicating leukemia, but are associated with a moderately
high risk for regimen-related toxicity (RRT) and transplant-related
mortality (TRM). Nonmyeloablative and reduced intensity regi-
mens, variably defined, have been used with resulting decreased
RRT and NRM, but also higher rates of relapse compared to mye-
loablative regimens. Thus, there is a need to explore alternative reg-
imens with sufficient intensity to mediate anti-leukemic activity
without increasing RRT or TRM. The objective of this ongoing
study was to determine the optimum dose of a new agent, treosul-
fan, in combination with fludarabine prior to allogeneic HCT in pa-
tients with acute myeloid (AML) or lymphoblastic leukemia (ALL)
or myelodysplastic syndrome (MDS). ‘‘Optimal’’ dose was deter-
mined by safety and efficacy, as defined by incidence of severe/fatal
RRT, graft failure and TRM. Thirty-six patients (8 children and 28adults$ 18 years), with a median of 41 (5–58) years, and diagnosed
with AML in first (n 5 19), second remission (n 5 7) or not in re-
mission (n 5 4), ALL in second remission (n 5 2) or MDS (n 5
4) have been treated. Patients were considered to be at high risk
for TRM because of aggressive therapy for a prior malignancy, co-
morbid conditions or previous HCT. Patients received treosulfan at
12 (n5 5) or 14 g/m2/day (n5 31) on days -6 to -4, and fludarabine
(30 mg/kg/day) on days -6 to -2. GVHD prophylaxis was with ta-
crolimus and methotrexate (n5 35) or cyclosporine and methotrex-
ate (n 5 1). Donors were HLA-matched siblings (n 5 19) or
unrelated volunteers (n 5 17); source of stem cells were bone mar-
row (n5 7) or filgrastim-mobilized peripheral blood cells (n5 29).
Neutrophil engraftment occurred at a median of 18 (11–30) days.
Grade II-IV acute graft-versus-host disease (GVHD) was observed
in 9 of 36 patients, and chronic GVHD in 8 of 23 evaluable patients
surviving beyond post-transplant day 80. Dose-limiting RRT was
observed in 1 of 36 patients (mucositis requiring intubation).
With a median follow-up of 118 (20–575) days, estimated one-
year overall and disease-free survival, relapse and TRM are 83%,
78%, 22% and 0%, respectively. Day-100 mortality is 6%. Treosul-
fan/fludarabine is a well-tolerated regimen with promising disease
control and low rates of RRT and TRM in patients with acute leu-
kemia and MDS. Further studies are warranted to evaluate the effi-
cacy of this regimen.279
MODIFICATION OF T CELL RESPONSES BY STEM CELL MOBILIZATION
REQUIRES DIRECT SIGNALLING OF THE T CELL BY G-CSF AND IL-10
MacDonald, K.P.A., Bofinger, H.M., Kuns, R.D., Morris, E.S.,
Don, A.L., Banovic, T., Hill, G.R. Queensland Institute of Medical Re-
search, Brisbane, Queensland, Australia.
G-CSF is increasingly described as a therapy for a diverse range
of diseases and although the mechanisms involved remain unclear,
IL-10 is thought to play a key role as a regulatory effector molecule.
Since G-CSF is used as a stem cell mobilizing agent, we generated
mixed radiation chimeras as stem cell donors in which haemato-
poietic or non-haematopoietic compartments were wild-type
(WT), IL-10-/-, G-CSFR-/- or combinations thereof. T cells from
donors mobilized with G-CSF had impaired ability to induce
GVHD only when the haematopoietic compartment was G-
CSFR competent, whereas G-CSFR signalling within the non-hae-
matopoietic compartment was irrelevant. Furthermore, we demon-
strate that the attenuation of T cell function requires direct
signalling of the T cell by G-CSF. Using G-CSF mobilized IL-
10-/- radiation chimeras as SCT donors, when the non-haemato-
poietic compartment was WT, T cells had impaired ability to
induce GVHD regardless of their ability to secrete IL-10. In con-
trast, T cells from chimeric donors in which the non-haemato-
poietic compartment was IL-10-/- universally induced severe
GVHD. Thus, the induction of regulatory T cell function by
stem cell mobilization occurs as a consequence of direct T cell sig-
nalling by G-CSF in conjunction with IL-10 derived from non-hae-
mopoietic cells. The IL-10 receptor is highly expressed by T cells,
particularly CD41CD251 regulatory T cells and their depletion
from G-CSF treated, but not control grafts, significantly increases
graft-versus-host disease (survival 25% v 75% Treg depleted vs
non-depleted donors P 5 0.002). These studies provide the expla-
nation for the profound effects of G-CSF on T cell function and
demonstrate that IL-10 is required to license regulatory function
but is not required as an effector molecule.280
SEROLOGICAL EVIDENCE OF HEPATITIS C IS ASSOCIATEDWITHWORSE
NON-RELAPSE MORTALITY AND OVERALL SURVIVAL AFTER ALLOGE-
NEIC STEM CELL TRANSPLANTATION
Ramos, C.A., Saliba, R.M., Khorshid, O., de Padua, L., Giralt, S.,
Andersson, B.S., Ueno, N.T., Shpall, E.J., Hosing, C., Qureshi, S.R.,
Champlin, R.E., de Lima, M. The University of Texas MD Anderson
Cancer Center, Houston, TX.
Active chronic hepatitis C (HC) is associated with perturbed im-
munity, but the influence of HC virus infection on the outcomes of
